ERO vs. NUTX

Last updated Jul 17, 2026

ERO (Ero Copper Corp) and NUTX (Nutex Health Inc) are both stocks. ERO operates in Copper (Basic Materials), while NUTX operates in Health Information Services (Healthcare). Over the past 3 years, ERO returned 4.09%/yr vs 39.94%/yr for NUTX. At a 0.13 correlation, their price movements are largely independent.

Performance

ERO vs. NUTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ero Copper Corp (ERO) and Nutex Health Inc (NUTX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ERO achieves a -13.33% return, which is significantly lower than NUTX's -0.13% return.

ERO

• 1D: -3.27%
• 1M: -18.54%
• 6M: -18.24%
• YTD: -13.33%
• 1Y: 71.95%
• 3Y*: 4.09%
• 5Y*: 5.23%
• 10Y*: —

NUTX

• 1D: -6.59%
• 1M: 14.13%
• 6M: 0.12%
• YTD: -0.13%
• 1Y: 57.96%
• 3Y*: 39.94%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

ERO vs. NUTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
ERO Ero Copper Corp	-13.33%	109.87%	-14.63%	14.84%	-11.75%
NUTX Nutex Health Inc	-0.13%	419.47%	17.37%	-90.53%	-81.82%

Correlation

The correlation between ERO and NUTX is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.18
Correlation (3Y) Calculated over the trailing 3-year period	0.16
Correlation (All Time) Calculated using the full available price history since Apr 4, 2022	0.13

Fundamentals

Market Cap ERO : $2.56B NUTX : $978.89M
EPS ERO : $2.79 NUTX : $20.14
PE Ratio ERO : 8.78 NUTX : 8.16
PEG Ratio ERO : 0.09 NUTX : 0.07
PS Ratio ERO : 2.77 NUTX : 0.89
Total Revenue (TTM) ERO : $925.20M NUTX : $879.95M
Gross Profit (TTM) ERO : $394.67M NUTX : $417.67M
EBITDA (TTM) ERO : $528.87M NUTX : $275.94M

Return for Risk

ERO vs. NUTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ERO

ERO Risk / Return Rank: 76
ERO Sharpe Ratio Rank: 80
ERO Sortino Ratio Rank: 75
ERO Omega Ratio Rank: 74
ERO Calmar Ratio Rank: 78
ERO Martin Ratio Rank: 75

NUTX

NUTX Risk / Return Rank: 67
NUTX Sharpe Ratio Rank: 66
NUTX Sortino Ratio Rank: 68
NUTX Omega Ratio Rank: 67
NUTX Calmar Ratio Rank: 67
NUTX Martin Ratio Rank: 65

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ERO vs. NUTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ero Copper Corp (ERO) and Nutex Health Inc (NUTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	ERO	NUTX	Difference
Sharpe ratio: Return per unit of total volatility	1.25	0.63	+0.62
Sortino ratio: Return per unit of downside risk	1.74	1.45	+0.29
Omega ratio: Gain probability vs. loss probability	1.22	1.18	+0.04
Calmar ratio: Return relative to maximum drawdown	1.90	1.07	+0.83
Martin ratio: Return relative to average drawdown	3.93	2.09	+1.85

ERO vs. NUTX - Sharpe Ratio Comparison

The current ERO Sharpe Ratio is 1.25, which is higher than the NUTX Sharpe Ratio of 0.63. The chart below compares the historical Sharpe Ratios of ERO and NUTX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

ERO vs. NUTX - Drawdown Comparison

The maximum ERO drawdown since its inception was -67.17%, smaller than the maximum NUTX drawdown of -99.93%. Use the drawdown chart below to compare losses from any high point for ERO and NUTX.

Drawdown Indicators

	ERO	NUTX	Difference
Max Drawdown Largest peak-to-trough decline	-67.17%	-99.93%	+32.76%
Max Drawdown (1Y) Largest decline over 1 year	-37.97%	-54.32%	+16.35%
Max Drawdown (3Y) Largest decline over 3 years	-59.84%	-93.55%	+33.71%
Max Drawdown (5Y) Largest decline over 5 years	-60.24%	—	—
Current Drawdown Current decline from peak	-35.52%	-97.26%	+61.74%
Average Drawdown Average peak-to-trough decline	-27.07%	-97.18%	+70.11%
Ulcer Index Depth and duration of drawdowns from previous peaks	18.35%	27.87%	-9.52%

Volatility

ERO vs. NUTX - Volatility Comparison

The current volatility for Ero Copper Corp (ERO) is 16.89%, while Nutex Health Inc (NUTX) has a volatility of 19.43%. This indicates that ERO experiences smaller price fluctuations and is considered to be less risky than NUTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ERO	NUTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.89%	19.43%	-2.54%
Volatility (6M) Calculated over the trailing 6-month period	48.84%	60.72%	-11.88%
Volatility (1Y) Calculated over the trailing 1-year period	57.90%	92.22%	-34.32%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	55.23%	190.16%	-134.93%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	59.39%	190.16%	-130.77%

Dividends

ERO vs. NUTX - Dividend Comparison

Neither ERO nor NUTX has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

ERO vs. NUTX - Profitability Comparison

The chart below illustrates the profitability comparison between Ero Copper Corp and Nutex Health Inc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ERO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Ero Copper Corp reported a gross profit of 103.33M and revenue of 259.52M. Therefore, the gross margin over that period was 39.8%.

NUTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Nutex Health Inc reported a gross profit of 91.73M and revenue of 216.49M. Therefore, the gross margin over that period was 42.4%.

ERO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Ero Copper Corp reported an operating income of 90.17M and revenue of 259.52M, resulting in an operating margin of 34.7%.

NUTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Nutex Health Inc reported an operating income of 81.27M and revenue of 216.49M, resulting in an operating margin of 37.5%.

ERO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Ero Copper Corp reported a net income of 107.26M and revenue of 259.52M, resulting in a net margin of 41.3%.

NUTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Nutex Health Inc reported a net income of 46.81M and revenue of 216.49M, resulting in a net margin of 21.6%.

Frequently Asked Questions

Can I hold both ERO and NUTX in my portfolio?

ERO and NUTX have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ERO or NUTX?

NUTX has higher volatility (19.43%) compared to ERO (16.89%). In terms of maximum drawdown, ERO dropped -67.17% vs NUTX's -99.93%.

Which has better risk-adjusted returns?

ERO currently has the higher Sharpe Ratio (1.25 vs 0.63), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.